Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Tissue Ablation: Applications and Perspectives (Adv. Mater. 32/2024)
Çevik, Enes , Demirlenk, Yusuf Mert , Atar, Dila , Saini, Gia , Sheth, Rahul A. , Keum, Hyeongseop , Kim, Jinjoo , Deipolyi, Amy R. , Öklü, Rahmi

Advanced Materials | August 8, 2024 | Volume: 36 | Issue: 32 | Pages: No page available

10.1002/adma.202470259 Get It

Another Vital Reason to Treat Hypertension: Preventing Intracranial Artery Dissections
Keser, Zafer , Keser, Zafer

American Journal of Hypertension | August 8, 2024 | Volume: 37 | Issue: 12 | Pages: 943-944

10.1093/ajh/hpae104 | PMID 39110033 Get It

Perceptions, prevalence, and patterns of cannabis use among cancer patients treated at 12 NCI-Designated Cancer Centers
Ellison, Gary L. , Helzlsouer, Kathy J. , Rosenfield, Sonia , Cullen, Jennifer, Doran, Neal , Ebbert, Jon O. , Egan, Kathleen M. , McDaniels‐Davidson, Corinne , Hernandez-Ortega, Nicholas, Salz, Talya , Vidot, Denise C , Zylla, Dylan M. , Rosenfield, Sonia M , Doran, Neal , McDaniels-Davidson, Corinne , Kim, Yun , Ashare, Rebecca L. , Blaes, Anne , Heffner, Jaimee L. , Lee, Richard T. , McClure, Erin A. , Meghani, Salimah H. , Newcomb, Polly A. , Nugent, Shannon M. , Worster, Brooke K. , Zylla, Dylan

JNCI Monographs | August 7, 2024 | Volume: 2024 | Issue: 66 | Pages: 202-217

10.1093/jncimonographs/lgae029 | PMID 39108244 Get It

Abstract Background The legal climate for cannabis use has dramatically changed with an increasing number of states passing legislation legalizing access for medical and recreational use. Among cancer patients, cannabis is often used to ameliorate adverse effects of cancer treatment. Data are limited on the extent and type of use among cancer patients during treatment and the perceived benefits and harms. This multicenter survey was conducted to assess the use of cannabis among cancer patients residing in states with varied legal access to cannabis. Methods A total of 12 NCI-Designated Cancer Centers, across states with varied cannabis-access legal status, conducted surveys with a core questionnaire to assess cannabis use among recently diagnosed cancer patients. Data were collected between September 2021 and August 2023 and pooled across 12 cancer centers. Frequencies and 95% confidence intervals for core survey measures were calculated, and weighted estimates are presented for the 10 sites that drew probability samples. Results Overall reported cannabis use since cancer diagnosis among survey respondents was 32.9% (weighted), which varied slightly by state legalization status. The most common perceived benefits of use were for pain, sleep, stress and anxiety, and treatment side effects. Reported perceived risks were less common and included inability to drive, difficulty concentrating, lung damage, addiction, and impact on employment. A majority reported feeling comfortable speaking to health-care providers though, overall, only 21.5% reported having done so. Among those who used cannabis since diagnosis, the most common modes were eating in food, smoking, and pills or tinctures, and the most common reasons were for sleep disturbance, followed by pain and stress and anxiety with 60%-68% reporting improved symptoms with use. Conclusion This geographically diverse survey demonstrates that patients use cannabis regardless of its legal status. Addressing knowledge gaps concerning benefits and harms of cannabis use during cancer treatment is critical to enhance patient-provider communication.
Evaluation and Management of Pelvic Osteomyelitis in Stage IV Pressure Injuries: A Multidisciplinary Collaborative Approach
Zein, Said El , Melin, Matthew M , Tran, Nho V. , Rose, Peter S. , Berbari, Elie F. , El Zein, Said , Suh, Gina A.

Clinical Infectious Diseases | August 7, 2024 | Volume: 79 | Issue: 3 | Pages: e11-e26

10.1093/cid/ciae394 | PMID 39325647 Get It

Abstract Managing pelvic osteomyelitis (POM) in the setting of stage IV pressure injuries requires multidisciplinary evaluation as well as patient and caregiver engagement and is complicated by the lack of high-evidence data to guide best practices. In this review, we describe our approach to pressure injury and POM evaluation and management through multidisciplinary collaboration and highlight areas of future research that are necessary to enhance patient outcomes, reduce healthcare costs, and improve the quality of life of those affected by POM.
Nodular regenerative hyperplasia: The role of the CK7 immunohistochemistry pattern of expression in diagnosis
Bartow, Brooke B., Dhall, Deepti, Lee, Goo , Garapati, Manjula, Patel, Chirag , Diffalha, Sameer Al , Patel, Chirag R

American Journal of Clinical Pathology | August 7, 2024 | Volume: 163 | Issue: 2 | Pages: 196-204

10.1093/ajcp/aqae110 | PMID 39213447 Get It

Abstract Objectives Nodular regenerative hyperplasia (NRH) is a rare vascular disorder of the liver. Clinically, patients present with portal hypertension with or without a cholestatic pattern of injury. Histologically, the liver parenchyma is composed of small nodules of hypertrophic hepatocytes surrounded by atrophic hepatocytes without significant fibrosis. Nodular regenerative hyperplasia is a difficult diagnosis on biopsy specimens, but biopsy remains the gold standard for diagnosis. In this retrospective review, cytokeratin 7 (CK7) immunohistochemistry (IHC) was used to aid in the diagnosis and further characterization of NRH and NRH-like changes. Methods The H&E-stained slides, reticulin, and CK IHC were reviewed for 22 cases. The percentage of hepatocytes staining for CK7 (0%-100%), the location of staining (centrilobular hepatic progenitor cells vs periportal/bile ductular reaction), and the pattern of staining distribution (patchy or diffuse) were recorded for comparison. Results Of the 22 cases, 9 were CK7 positive. Cases of NRH, however, expressed various degrees of CK7 positivity in centrilobular hepatic progenitor cells, unlike NRH-like changes, which were either CK7 negative or CK7 positive in periportal hepatocytes or in areas of bile ductular reaction. Conclusions In cases with the appropriate clinical history and histology, CK7 immunohistochemistry can be performed to distinguish nodular regenerative hyperplasia (primary) and NRH-like changes (secondary). In difficult cases, CK7 positivity in centrilobular hepatic progenitor cells can help confirm the diagnosis of NRH. These data support NRH as a true entity with a distinct pathophysiology from NRH-like changes.
“Down Syndrome is Not a Curse”: parent Perspectives on the Medicalization of Down Syndrome
Riggan, Kirsten A. , Michie, Marsha , Allyse, Megan , Allyse, Megan A , Riggan, Kirsten A

AJOB Empirical Bioethics | August 7, 2024 | Volume: 16 | Issue: 1 | Pages: 10-21

10.1080/23294515.2024.2388533 | PMID 39110899 Get It

“Genetic tumor syndromes of the head and neck: Update in the genomic era”
Brahmbhatt, Sneh , Shetty, Dhruv , Bhatt, Alok A. , Bhatt, Alok A , Agarwal, Amit , Desai, Amit

The Neuroradiology Journal | August 7, 2024 | Volume: 38 | Issue: 3 | Pages: 277-290

10.1177/19714009241269462 | PMID 39110991 Get It

Genetic tumor syndromes are due to inherited genetic mutations, which have recently come to the attention of clinicians due to the widespread adoption of DNA sequencing, ultimately leading to imaging for surveillance. As a result, radiologists must be familiar with the clinical, genetic, and radiologic features of these syndromes. This article reviews genetic tumor syndromes of the head and neck according to the recently updated WHO’s 5th edition.
Abstract 460: Adventitial Delivery of Nanoparticle Hydrogel-calcitriol Attenuates Restenosis in a Murine Angioplasty Model
Zhao, Chenglei , Singh, Avishek , Misra, Avanish, Simeon, Michael L. , Li, Yiqing , Cai, Chuanqi , Kilari, Sreenivasulu , Misra, Sanjay

Arteriosclerosis, Thrombosis, and Vascular Biology | August 7, 2024 | Volume: 40 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.40.suppl_1.460 Get It

Background: Percutaneous transluminal angioplasty (PTA) is the first-line treatment for arteriovenous fistula (AVF) failure and immaturation. High rate of restenosis occurs post PTA procedure caused by venous neointimal hyperplasia (VNH), and decrease the durability of it. Failed AVF showed increased gene expression of Ier3. Poly lactic- co -glycolic acid nanoparticles (PLGA) loaded with 1,25-dihydroxyvitamin D 3 (1,25 NP) can inhibit Ier3 gene expression. Hypothesis: Adventitial delivery of 1,25 NP in hydrogel will reduce venous stenosis in a murine PTA model. Methods: Male C57BL/6J mice underwent partial nephrectomy at day -42 and arteriovenous fistula (AVF) creation at day -14. At day 0, mice were randomized to vehicle group (PTA + PLGA hydrogel) or treatment group (PTA + 1,25 NP hydrogel). Mice were euthanized at day 3 for gene expression analysis and at day 21 for histopathological analysis. Doppler ultrasound was performed weekly to evaluate AVF patency and function. Results: At day 3, PTA + 1,25 NP treated vessels had a significant decrease in the gene expression of Ier3 compared to controls. At day 21, 1,25 NP treated outflow veins had increased lumen vessel area, apoptosis, and higher peak systolic velocity, but decrease in neointimal area/media area ratio, fibroblasts, pro-inflammatory macrophages (M1), fibrosis (picrosirius red staining) and cellular proliferation. Conclusion: Adventitial delivery of 1,25 NP plus PTA has the ability to reduce restenosis and VNH formation. This protective effect is related to inhibition of Ier3 gene expression which modulates vascular inflammation and fibrosis post PTA.
Myeloma Therapy for Monoclonal Gammopathy of Thrombotic Significance
Salmasi, Giselle, Murray, David , Padmanabhan, Anand , Padmanabhan, Anand , Salmasi, Giselle

New England Journal of Medicine | August 7, 2024 | Volume: 391 | Issue: 6 | Pages: 570-571

10.1056/nejmc2406453 | PMID 39115069 Get It

Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
Hoff, Fieke W. , Blum, William , Huang, Ying , Welkie, Rina Li , Swords, Ronan , Traer, Elie , Stein, Eytan M. , Lin, Tara L. , Patel, Prapti A. , Collins, Robert H. , Baer, Maria R. , Arellano, Martha , Odenike, Olatoyosi , Redner, Robert L. , Kovacsovics, Tibor , Deininger, Michael W. , Olin, Rebecca L. , Foran, James M. , Schiller, Gary J. , Curran, Emily , Koenig, Kristin L , Heerema, Nyla A. , Chen, Timothy L. , Martycz, Molly , Stefanos, Mona , Marcus, Sonja G., Rosenberg, Leonard, Burd, Amy , Yocum, Ashley O. , Borate, Uma , Byrd, John C. , Madanat, Yazan F. , Huang, Ying , Byrd, John C. , Duong, Vu H , Deininger, Michael , Zeidner, Joshua F , Smith, Catherine C , Koenig, Kristin L , Druker, Brian J , Mims, Alice S , Madanat, Yazan , Traer, Elie , Lin, Tara L , Byrd, John C , Archer, Kellie J. , Duong, Vu H. , Stock, Wendy , Zeidner, Joshua F. , Smith, Catherine C. , Marcus, Sonja G., Levine, Ross L.

Blood Advances | August 7, 2024 | Volume: 8 | Issue: 20 | Pages: 5297-5305

10.1182/bloodadvances.2024013685 | PMID 39110987 Get It

Abstract Although the 2022 European LeukemiaNet (ELN) acute myeloid leukemia (AML) risk classification reliably predicts outcomes in younger patients treated with intensive chemotherapy, it is unclear whether it applies to adults ≥60 years treated with lower-intensity treatment (LIT). We aimed to test the prognostic impact of ELN risk in patients with newly diagnosed (ND) AML aged ≥60 years given LIT and to further refine risk stratification for these patients. A total of 595 patients were included: 11% had favorable-, 11% intermediate-, and 78% had adverse-risk AML. ELN risk was prognostic for overall survival (OS) (P < .001) but did not stratify favorable- from intermediate-risk (P = .71). Within adverse-risk AML, the impact of additional molecular abnormalities was further evaluated. Multivariable analysis was performed on a training set (n = 316) and identified IDH2 mutation as an independent favorable prognostic factor, and KRAS, MLL2, and TP53 mutations as unfavorable (P < .05). A “mutation score” was calculated for each combination of these mutations, assigning adverse-risk patients to 2 risk groups: −1 to 0 points (“Beat-AML intermediate”) vs 1+ points (“Beat-AML adverse”). In the final refined risk classification, ELN favorable- and intermediate-risk were combined into a newly defined “Beat-AML favorable-risk” group, in addition to mutation scoring within the ELN adverse-risk group. This approach redefines risk for older patients with ND AML and proposes refined Beat-AML risk groups with improved discrimination for OS (2-year OS, 48% vs 33% vs 11%, respectively; P < .001), providing patients and providers additional information for treatment decision-making.